Abstract

Research Article

B-ultrasound-guided Intrahepatic Infusion of Autologous Bone Marrow Cells for Decompensated Cirrhosis

Baochi Liu*, Xiong Gao, Yuanhuai Chen, Qiqiang Dong, Jingbo Wang and Baisong Zhao

Published: 12 July, 2024 | Volume 7 - Issue 1 | Pages: 001-006

Objective: To study the therapeutic effect of B-ultrasound-guided intrahepatic infusion of autologous bone marrow nucleated cells on decompensated cirrhosis. 
Methods: To observe the clinical treatment of 75 cases of decompensated cirrhosis. Among them, 30 cases received routine liver protection and diuretic treatment. 45 cases were treated by percutaneous transhepatic infusion of autologous bone marrow nucleated cells under the guidance of B ultrasound. There were no significant differences in liver function and blood routine indexes between the two groups before treatment (p > 0.05). 
Results: The indexes of liver function and blood routine at different time periods of 1 month, 3 months, 6 months, and 12 months in the conventional treatment group did not change significantly. 6 cases died of liver failure within 1 year, the fatality rate was 20%. The indexes of liver function and blood routine of percutaneous liver transhepatic infusion of autologous bone marrow nucleated cells at 1 month, 3 months, 6 months, and 12 months under the guidance of B-ultrasound were significantly better than those of the conventional treatment group (p < 0.05). One case died of gastrointestinal bleeding in the group of percutaneous transhepatic infusion of autologous bone marrow nucleated cells guided by B ultrasound, with a fatality rate of 2.5%. Compared with the conventional treatment group, there were significant differences (p < 0.05). 
Conclusion: Conventional drug therapy has no obvious effect on decompensated cirrhosis. Intrahepatic infusion of bone marrow nucleated cells can significantly promote liver function reconstruction in decompensated cirrhosis.

Read Full Article HTML DOI: 10.29328/journal.jbmr.1001017 Cite this Article Read Full Article PDF

Keywords:

Decompensation period of cirrhosis; Bone marrow nucleated cells; Transplantation; B-ultrasound guidance; Intrahepatic infusion

References

  1. Pantham G, Mullen KD. Practical Issues in the Management of Overt Hepatic Encephalopathy. Gastroenterol Hepatol (N Y). 2017;13(11):659-665. Available from: https://www.gastroenterologyandhepatology.net/archives/november-2017/practical-issues-in-the-management-of-overt-hepatic-encephalopathy/
  2. Bannas P, Roldán-Alzate A, Johnson KM, Woods MA, Ozkan O, Motosugi U, et al. Longitudinal Monitoring of Hepatic Blood Flow before and after TIPS by Using 4D-Flow MR Imaging. Radiology. 2016;281(2):574-582. Available from: https://pubmed.ncbi.nlm.nih.gov/27171019/
  3. Cavași A, Mercea V, Anton O, Puia IC. Therapeutic Challenges for Symptomatic Portal Cavernoma Cholangiopathy. J Gastrointestin Liver Dis. 2016;25(3):395-399. Available from: https://www.jgld.ro/jgld/index.php/jgld/article/view/1079
  4. Owen JM, Gaba RC. Transjugular Intrahepatic Portosystemic Shunt Dysfunction: Concordance of Clinical Findings, Doppler Ultrasound Examination, and Shunt Venography. J Clin Imaging Sci. 2016;6:29. Available from: https://europepmc.org/article/PMC/4977976
  5. Pan HC, Chen YJ, Lin JP, Tsai MJ, Jenq CC, Lee WC, et al. Proteinuria can predict prognosis after liver transplantation. BMC Surg. 2016;16(1):63. Available from: https://bmcsurg.biomedcentral.com/articles/10.1186/s12893-016-0176-8
  6. Takami T, Terai S, Sakaida I. Stem cell therapy in chronic liver disease. Curr Opin Gastroenterol. 2012;28(3):203-208. Available from: https://journals.lww.com/co-gastroenterology/Abstract/2012/05000/Stem_cell_therapy_in_chronic_liver_disease.6.aspx
  7. Esch JS, Knoefel WT, Klein M, Ghodsizad A, Fuerst G, Poll LW, et al. Portal application of autologous CD133+ bone marrow cells to the liver: a novel concept to support hepatic regeneration. Stem Cells. 2005;23(4):463-470. Available from: https://pubmed.ncbi.nlm.nih.gov/15790766/
  8. Liu B, Chen X, Shi Y. Curative Effect of Hepatic Portal Venous Administration of Autologous Bone Marrow in AIDS Patients with Decompensated Liver Cirrhosis. Cell Death Dis. 2013;4. Available from: https://www.nature.com/articles/cddis2013261
  9. Liu B, Cheng M, Chen X, Li L, Si YH, Wang SJ, et al. Autologous bone marrow cell transplantation in the treatment of HIV patients with compensated cirrhosis. Biosci Rep. 2020;40. Available from: https://doi.org/10.1042/BSR20191316
  10. Liu BC, Lang L, Li L, et al. Clinical observation of autologous bone marrow transplantation for decompensated cirrhosis. J Hepatobiliary Surg. 2020;32(10):585-589.
  11. Nicolas CT, Wang Y, Nyberg SL. Cell therapy in chronic liver disease. Curr Opin Gastroenterol. 2016;32(3):189-194. Available from: https://europepmc.org/article/MED/26950359
  12. Cantz T, Sharma AD, Ott M. Concise review: Cell therapies for hereditary metabolic liver diseases-concepts, clinical results, and future developments. Stem Cells. 2015;33:1055-1062. Available from: https://repository.helmholtz-hzi.de/bitstream/handle/10033/550489/Cantz%2C%20Sharma%20and%20Ott_final.pdf?sequence=1
  13. Kim JK, Kim SJ, Kim Y, Chung YE, Park YN, Kim HO, et al. Long-Term Follow-Up of Patients After Autologous Bone Marrow Cell Infusion for Decompensated Liver Cirrhosis. Cell Transplant. 2017;26:1059-1066. Available from: https://pubmed.ncbi.nlm.nih.gov/28120743/
  14. Mullen KD, Sanyal AJ, Bass NM, Nathan M Bass, Fred F Poordad, et al. Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy. Clin Gastroenterol Hepatol. 2014;12(8):1390-1397.e2. Available from: https://www.cghjournal.org/article/S1542-3565%2813%2901968-X/pdf
  15. Pan XN, Zheng LQ, Lai XH. Bone marrow-derived mesenchymal stem cell therapy for decompensated liver cirrhosis: a meta-analysis. World J Gastroenterol. 2014;20:14051-14057. Available from: https://www.wjgnet.com/1007-9327/full/v20/i38/14051.htm
  16. Levine P, McDaniel K, Francis H, Kennedy L, Alpini G, Meng F. Molecular mechanisms of stem cell therapy in alcoholic liver disease. Dig Liver Dis. 2014;46:391-397. Available from: https://www.sciencedirect.com/science/article/abs/pii/S1590865813006701
  17. Liu BC. Treatment and surgical techniques of decompensated liver cirrhosis after hepatitis. Int J Surg. 2017;44(1):35-37.
  18. Nicolas CT, Hickey RD, Chen HS, Mao SA, Lopera Higuita M, Wang Y, Nyberg SL. Concise Review: Liver Regenerative Medicine: From Hepatocyte Transplantation to Bioartificial Livers and Bioengineered Grafts. Stem Cells. 2017;35(1):42-50. Available from: https://academic.oup.com/stmcls/article/35/1/42/6421112
  19. Liu BC, Li L, Si YH, et al. Treatment of decompensated cirrhosis with cholecystolithiasis by autologous bone marrow intrahepatic infusion. J Hepatobiliary Pancreat Sci. 2016;28(1):10-12.
  20. Lei L, Si Y, Cheng M, Lang L, Li A, Liu B. Therapeutic effect of autologous bone marrow cells injected into the liver under the guidance of B ultrasound in the treatment of HBV-related decompensated liver cirrhosis. Exp Ther Med. 2022;24:633. Available from: https://pubmed.ncbi.nlm.nih.gov/36160909/

Figures:

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?